American Kidney Fund Launches National Awareness Campaign Amid Rising Disease Prevalence

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

American Kidney Fund launches "Kidneys Count" campaign March 1, 2026, promoting early detection and prevention of kidney disease affecting 1 in 7 American adults.

American Kidney Fund Launches National Awareness Campaign Amid Rising Disease Prevalence

The American Kidney Fund (AKF) is launching a comprehensive public health initiative on March 1, 2026, aimed at increasing awareness of kidney disease, which affects approximately 1 in 7 American adults. The campaign, titled "Kidneys Count," focuses on promoting early detection and prevention strategies through direct engagement with the public and healthcare providers. The initiative encourages Americans to prioritize kidney health discussions with their medical practitioners and to understand their individual risk factors.

As part of the broader campaign, the AKF will host Kidney Action Week from March 2-5, 2026, featuring a series of expert-led sessions dedicated to kidney disease management and treatment options. These educational events are designed to provide evidence-based information to both patients and caregivers seeking to understand disease progression and available medical interventions.

The timing of the campaign reflects growing concerns about chronic kidney disease prevalence in the United States. By emphasizing preventive measures and early medical intervention, the AKF aims to address the significant public health burden associated with undiagnosed or late-stage kidney disease, which can lead to substantial healthcare costs and complications if left untreated.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 27

Related Coverage

GlobeNewswire Inc.

XORTX Shareholders Back 5-to-1 Consolidation to Avert NASDAQ Delisting

XORTX shareholders approved a 5-to-1 share consolidation to maintain NASDAQ compliance, reducing shares from 6.96M to 1.39M ahead of April 2026 deadline.

XRTX
The Motley Fool

International High-Dividend ETF Outpaces S&P 500 as Retirees Seek Yield

$VYMI offers 3.3% dividend yield with 1,500+ stocks and 0.07% fees, outperforming S&P 500 with 24% annual returns for income-focused retirees.

NVSRHHBYSHEL
GlobeNewswire Inc.

Amphista Therapeutics Showcases Next-Gen Cancer Degraders at AACR Meeting

Amphista Therapeutics presents three programs at AACR 2026, including oral presentation on AMX-883 BRD9 degrader for AML treatment.

LLYNVS
GlobeNewswire Inc.

Biotech Veteran Ramanayake Takes Helm at Anaveon as Immune Reprogramming Firm Pursues Clinical Trials

Anaveon appoints veteran biotech executive Thaminda Ramanayake as CEO to guide lead candidate ANV200 through clinical development for autoimmune and inflammatory diseases.

PFENVSBNTX
GlobeNewswire Inc.

Novartis Showcases Dermatology Pipeline Momentum With Early-Relief Data at AAD 2026

Novartis presents 20+ abstracts at AAD 2026, highlighting rapid symptom relief with Rhapsido and long-term efficacy data for Cosentyx across multiple skin conditions.

NVS
The Motley Fool

RTW Investments Bets $193M on Apellis Rebound Despite 29% Stock Decline

RTW Investments establishes $193M position in Apellis Pharmaceuticals despite 29% stock decline, betting on turnaround potential of $689M revenue-generating biotech.

ARGXAPLSMDGL